Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H N Glassman

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
American Journal of Hypertension|July 1, 1988
Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertensionR R Luther, H N Glassman, C B Estep, et al.
Clinical Therapeutics|January 1, 1988
Effect of age on the pharmacokinetics of orally and intravenously administered terazosinL T Sennello, R C Sonders, H N Glassman, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1986
Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapyR R Luther, H N Glassman, W D Sperzel, et al.
Hypertension (Dallas, Tex. : 1979)|June 1, 1990
Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertensionR S Boger, H N Glassman, J H Cavanaugh, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
American Journal of Hypertension|July 1, 1988
Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertensionR R Luther, H N Glassman, C B Estep, et al.
Clinical Therapeutics|January 1, 1988
Effect of age on the pharmacokinetics of orally and intravenously administered terazosinL T Sennello, R C Sonders, H N Glassman, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1986
Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapyR R Luther, H N Glassman, W D Sperzel, et al.
Hypertension (Dallas, Tex. : 1979)|June 1, 1990
Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertensionR S Boger, H N Glassman, J H Cavanaugh, et al.
Pageof 3